New research shows a correlation between compounded weight loss and diabetes injectables and increased adverse events. GIlead Sciences is suing another New York City pharmacy that allegedly sold counterfeit HIV medicine.
Read MoreThe FDA has issued a warning to the operators of the online pharmacy www.thesafepills.org for illegally selling unapproved and misbranded opioid medications, including tapentadol products marketed as Aspadol and Typendol. These unauthorized drugs, sold without a prescription, pose significant health risks such as overdose, addiction, and even death.
Read More
One of SafeChain’s three owners pleaded guilty. The company collected secondhand HIV medicines from patients and resold them to licensed U.S. pharmacies, forging paperwork to make them look legitimate.
Read More
A Kentucky doctor treated weight loss patients with research chemicals; CBP seized 90,000 alprazolam pills being smuggled into the U.S.
Read More
The FDA and Novo Nordisk are warning the public about counterfeit Ozempic injections circulating in the U.S. drug supply chain. The falsified products, labeled with lot number PAR0362 and serial numbers beginning with 51746517, were seized by the FDA on April 9, 2025. Their contents and safety are unverified and pose serious health risks.
Read More
PSM is seeking input on developing a set of best practices to reduce sales of counterfeit and diverted medicines on online pharmacy-to-pharmacy marketplaces.
Read More
The FDA announced that it had seized counterfeit Ozempic injections on April 9. PSM testified at a congressional hearing.
Read More
A study examined the 130 enforcement actions undertaken by the U.S. Food and Drug Administration’s Office of Criminal Investigations from 2016 through 2021.
Read More
The state of Colorado submitted a revised application to the U.S. Food and Drug Administration to operation a Canadian drug importation plan in March. This blog post examines how the state’s application has changed over the years.
Read More
A March 12, 2025 memo said the state had paid more than $150,000 defending itself in a lawsuit Amgen had filed over plans to set an upper payment limit on its rheumatoid arthritis treatment, Enbrel.
Read More